Does Medicare Cover Ozempic, Wegovy & Zepbound?

Whether Medicare covers your GLP-1 depends almost entirely on why it was prescribed — not on which drug is in the pen. By federal law, a standard Medicare Part D plan cannot pay for a medicine used for weight loss alone. So Wegovy or Zepbound prescribed only to help you lose weight are generally not covered the way an ordinary prescription is. Yet the same molecules are covered when they treat a recognized condition: Ozempic, Mounjaro, and Rybelsus for type 2 diabetes; Wegovy to lower heart-attack and stroke risk; and Zepbound for obstructive sleep apnea. And since July 1, 2026, a temporary Medicare demonstration called the GLP-1 Bridge offers Wegovy, the Zepbound KwikPen, and the pill Foundayo for weight loss at a flat $50 a month — outside your normal Part D plan.

This guide is information, not medical or insurance advice. Coverage rules change often; every figure below is dated, and you should confirm the specifics with your own plan and prescriber before making any decision.

The rule that decides everything: your diagnosis, not the drug

Medicare has excluded drugs used for weight loss since Part D began — the category sits alongside a small group of drugs that federal law lets plans leave out. That single rule explains why two people can be handed the exact same pen and get opposite answers at the pharmacy counter. If the prescription is written for a covered medical condition, a Part D plan can pay for it. If the only reason is to lose weight, the plan legally cannot.

A covered indication is necessary but not automatic. Even for diabetes, plans still apply their own formulary rules: the drug has to be on your plan's list, at a tier you can afford, and it may require prior authorization, step therapy, or quantity limits. Medicare Advantage (Part C) plans include Part D drug coverage and follow the same law, so the rules are identical there.

Medicare coverage by drug and reason (as of July 2026)

This table shows the practical status of each brand by the reason it is prescribed. "Covered by Part D" always means if it is on your plan's formulary — check yours before you count on it.

What each covered indication actually requires

Type 2 diabetes — the broadest coverage

This is where Medicare coverage is most established. Type 2 diabetes is a recognized indication for Ozempic, Mounjaro, and Rybelsus, and most Part D plans list at least one of them. Note the brand names carefully: Wegovy and Zepbound are not diabetes drugs, even though they contain the same active ingredients as Ozempic and Mounjaro. Your prescriber and pharmacist match the specific brand to the diagnosis, so the label on the box matters as much as the molecule inside it.

Heart-attack and stroke risk — Wegovy since 2024

On March 8, 2024, the FDA approved Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have established heart disease and are overweight or obese — based on the SELECT trial of more than 17,600 people. Because that is a medical indication and not "weight loss alone," many Part D plans now cover Wegovy for it. The prior authorization typically has to document your heart-disease history, so ask your clinician to record it clearly. Our heart-health guide covers who this pathway tends to apply to.

Obstructive sleep apnea — Zepbound since 2024

On December 20, 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication ever approved for OSA. That created a coverage pathway some Part D plans honor, usually requiring a sleep study on file. It is not a weight-loss approval, so a plan covering it here is following the same diagnosis-based logic as everything above.

The Medicare GLP-1 Bridge: weight-loss coverage, for now

Here is the genuinely new part, and where a lot of older articles are now wrong. From July 1, 2026 through December 31, 2027, the Centers for Medicare & Medicaid Services (CMS) is running a temporary demonstration — the Medicare GLP-1 Bridge — that provides three weight-loss drugs for a flat $50 monthly copay: Wegovy, the Zepbound KwikPen, and the oral drug Foundayo (orforglipron). Notably, Ozempic and Mounjaro are not included — those stay diabetes-only for Medicare.

The Bridge runs outside your regular Part D benefit (Humana processes it centrally for CMS), so your plan does not have to opt in. To be eligible you must have Part D coverage, be 18 or older, and meet body-mass-index and related clinical criteria. There is a telling catch: you must not already be getting a GLP-1 through your Part D plan, and you must not have a diagnosis of type 2 diabetes, moderate-to-severe sleep apnea, or fatty-liver disease — because each of those already gives you a coverage route. That carve-out is the whole "diagnosis decides it" principle in one paragraph.

Two honest caveats. First, it is temporary — a demonstration scheduled to end December 31, 2027, and demonstrations can be changed or ended early. Second, the $50 you pay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap for 2026, so it sits alongside your regular drug spending rather than reducing it.

What about the BALANCE model?

You may see headlines about a bigger, permanent program called the BALANCE model. As of July 2026 it is partly real and partly on hold. The Medicaid side launched May 1, 2026, with states applying through July 31, 2026. The Medicare Part D side was originally set for January 2027 but CMS announced an indefinite delay on April 21, 2026. It would negotiate a lower price (around $245 for a 30-day supply) across more drugs, but for now it is emerging, not guaranteed — track updates through KFF rather than assuming it is live.

Medicaid is a separate system with its own state-by-state rules; roughly 13 state Medicaid programs covered GLP-1s for obesity as of January 2026 (per KFF), and that list changes from month to month. If you have Medicaid or dual Medicare-Medicaid coverage, check your state's program directly rather than relying on a national figure.

How to check your own coverage in five steps

1. Pull your plan's formulary. Use the Medicare Plan Finder on Medicare.gov or your plan's website and search the exact brand name — Ozempic versus Wegovy is not interchangeable here.
2. Read the flags. Note the drug's tier and any "PA" (prior authorization), "ST" (step therapy), or "QL" (quantity limit) codes; they predict the hoops ahead.
3. Match drug to diagnosis. Ask your prescriber to document the covered indication in your chart and on the prior-authorization form — the diagnosis code, not the drug, drives the decision.
4. Ask about the Bridge. If weight loss is the only reason, ask whether you qualify for the $50-a-month GLP-1 Bridge and how to enroll.
5. Estimate and appeal. Use our cost and coverage estimator to ballpark what you'll pay, and if you're denied, know your appeal rights.

For price context by brand, see Ozempic cost, Wegovy cost, and Zepbound cost. New to these drugs? Start with GLP-1s explained, compare Wegovy vs. Ozempic, or read up on the pill option in oral semaglutide.

When to talk to your doctor, and what to ask

Never start, stop, or switch a GLP-1 based on a coverage article — that's a conversation for you and your clinician. What this page can do is make that conversation productive. Bring three questions: Do I already meet a covered medical indication (diabetes, heart disease, or sleep apnea)? Which brand is on my plan's formulary at the lowest tier? And are you comfortable documenting my diagnosis on the prior authorization? If none of those fit and weight loss is the goal, ask specifically about the GLP-1 Bridge.

Coverage of these drugs is moving fast, and the numbers here are dated to July 2026 on purpose. Treat this as a map, not a guarantee: confirm every detail with your Part D plan's current formulary and your prescriber before you rely on it, and check KFF's live tracker for the latest changes. For the wider picture across insurers, see our GLP-1 insurance coverage guide.